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Previous studies indicated that upregulating TCRζ partially recovers T cell function in patients with leukemia. In this
study, we characterized the cytokine profile of TCRζ-transfected T cells from acute myeloid leukemia (AML) patients
by Quantibody®Array Glass Chip. Firstly, the significantly lower expression of TCRζ in CD3+/TCRζ+ cells from AML
patients was found. Increased secretion of IL-2, IL-8, IL-10, IL-13, IFN-γ, TNF-α, GM-CSF, growth-regulated oncogene
(GRO), MIP-1b, and regulated on activation, normal T cell expressed and secreted (RANTES) could be detected in T
cells from AML patients after TCRζ upregulating. We concluded that upregulating TCRζ in T cells from AML can alter
the secretion profile of cytokines and chemokine which are involved in T cell proliferation and activation.
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Acute myeloid leukemia (AML) is an aggressive disease
with an unfavorable prognosis [1–3]. T cell immunodefi-
ciency is a common characteristic in hematological ma-
lignancies which may be due to defective TCRζ. Previous
studies showed that TCRζupregulation could be induced
in CD3+T cells from AML patients by IL-2, IL-7, and IL-
12 [4]. In this study, we characterized the secretion profile
of cytokines and chemokines related to T cell activation in
TCRζ-IRES2-EGFP-transfected T cells from AML patients
after TCRζupregulation.
First, significantly lower TCRζ expression in CD3
+/TCRζ+ cells in AML (2.89 ± 2.6 %, n = 10) was found
in comparison with healthy individuals (87.38 ± 15.67 %,
n = 10) (p < 0.001) (Fig. 1a–c). This result further sup-
ported our previous finding that T cell immunodefi-
ciency might be due to low TCRζ signaling in T cells
[5–8].
CD3+T cells were sorted from PBMCs from four AML
patients (Additional file 1: Table S1) who had TCRζ
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creativecommons.org/publicdomain/zero/1.0/or IRES2-EGFP, respectively, by nucleofection [9]. Sig-
nificant upregulation of TCRζ in TCRζ-IRES2-EGFP-
transfected CD3+T cells was confirmed. Similar results
were found in TCRζ downstream target factor Zap-70
(Fig. 1d–f ). Thus, TCRζ gene transfection could directly
upregulate TCRζ and Zap-70 in T cells from AML
patients as previously found in CML [9].
Forced TCRζ chain expression can reverse TCR/
CD3-mediated signaling abnormalities and defective
IL-2 production in T cells [9, 10]. In this study, we used
Quantibody®Array Glass Chip (www.raybiotech.com)
to quantitatively measure 20 human cytokines and che-
mokines in supernatants from TCRζ-IRES2-EGFP-
transfected and IRES2-EGFP-transfected T cells from
AML patients (Additional file 2). Increased secretion
of IL-2, IL-8, IL-10, IL-13, IFN-γ, TNF-α, GM-CSF,
growth-regulated oncogene (GRO), MIP-1b, and regu-
lated on activation, normal T cell expressed and
secreted (RANTES) and decreased secretion of IL-5
were found, while the secretion level of IL-1α, IL-1β,
IL-4, IL-6, and IL-12 had no obvious change after
TCRζupregulation. Moreover, the changes in the secre-
tion levels of IL-10, MCP-1, MIP-1a, MMP-1, and
VEGF were different in different AML samples (Fig. 2).
After TCRζ transfection, the IFN-γ secretion level was
increased in all samples in the TCRζ-IRES2-EGFP group
(median 71.46 pg/mL) compared with the pIRES2-EGFPicle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://









Fig. 1 Expression of CD3+/TCRζ+ cells in PBMCs and expression of TCRζ and Zap-70 in TCRζ-transfected CD3+ T cells from patients with AML. a
MFI of CD3+/TCRζ+ in PBMCs from AML patients and healthy individuals (HI) (n =10). b Percentage of CD3+/TCRζ+ cells in PBMCs from a healthy
individual. c Percentage of CD3+/TCRζ+ in PBMCs from a patient with AML. d TCRζ gene expression levels. e Zap-70 gene expression level in
TCRζ-transfected CD3+ T cells and control cells. f TCRζ and Zap-70 protein expression in transfected CD3+ T cells from two AML samples and
control cells
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level of IFN-γ in T cells from different AML patients
was relatively different, ranging from 18.89 to
169.41 pg/mL in control cells and from 54.02 to
335.33 pg/mL in TCRζ-IRES2-EGFP cells. Thus, it could
be understood that the increased secretion of IFN-γ was
not statistically different in this study even though there
was an obvious change in its level. Similar characteristic
was found in TNF-α secretion level (Additional file 3:
Figure S1). Interestingly, we found that the level of GM-
CSF was significantly increased (21.63 ± 15.19 pg/mL
for TCRζ-IRES2-EGFP cells vs. 1.96 ± 1.83 pg/mL forpIRES2-EGFP cells) (p = 0.045) (Fig. 2), and IL-13,
which is secreted by activated T cells and has synergistic
effects with GM-CSF and G-CSF, was also upregulated
after TCRζ gene transfection (Fig. 2). Recently, increas-
ing data have shown that GM-CSF has a variety of
effects on the immune system including the activation
of T cells, maturation of dendritic cells, and the ability
to promote humoral and cell-mediated responses; thus,
it has been incorporated into immunotherapy strategies
[11, 12].
In conclusion, we characterized the profile of cytokines
and chemokines secretion in T cells after TCRζ gene
BA
Fig. 2 Detection of the IL-2, IL-5, IL-8, IL-10, IL-13, RANTES, GM-CSF, MIP-1b, IFN-γ, and TNF-α level secreted from T cells from AML patients using
Quantibody® array. a Fluorescence intensity (concentration) from laser scanner results. 1–4: four parallel wells for each sample. b The level of IL-2,
IL-5, IL-8, IL-10, IL-13, RANTES, GM-CSF, and MIP-1b secreted from T cells from four cases with AML
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tion and activation, such as IL-2, IFN-γ, and TNF-α, had
increased secretion after TCRζ upregulating. Moreover,
some of the Th1-associated CC subfamily chemokines,such as CCL4 and CCL5, may contribute to T cell acti-
vation via TCRζ upregulation. These results may further
support the idea of the effects of upregulating TCRζ in
T cell immunity.
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Additional file 1: Table S1. Clinical data of AML patients.
Additional file 2: Materials and methods.
Additional file 3: Figure S1. Detection of the IFN-γ and TNF-α level in
T cells from AML patients using Quantibody® array. A: Laser scanner
fluorescence intensity (concentration) results. 1–4: samples from four
cases with AML. B: The secretion level of IFN-γ and TNF-α in T cells from
four cases with AML.
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